NextCure, Inc. - NXTC STOCK NEWS

NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company focused on developing novel immunomedicines for cancer and immune-related diseases, will host a Virtual R&D Update Event on March 4 at 5:00 p.m. ET. Participants can join via conference call by calling (877) 665-6632 for US/Canada or (602) 563-8471 internationally, using Conference ID 6773907. A live webcast will be available on their website, with a replay accessible for 30 days post-event. NextCure aims to innovate treatments for patients unresponsive to existing therapies.

NextCure, a clinical-stage biopharmaceutical company (Nasdaq: NXTC), announced the appointment of Dr. Han Myint as chief medical officer. Dr. Myint will lead the clinical development of key products including NC318 and NC410. His previous roles include senior positions at Celgene and NexImmune, where he contributed to multiple FDA-approved products. NextCure focuses on developing first-in-class immunomedicines for cancer and immune-related diseases using its FIND-IO™ platform.

NextCure, Inc. (Nasdaq: NXTC) announced updates on the clinical trial of NC318, an immunomedicine targeting Siglec15 for cancer treatment. The company is refining its trial plans to better identify S15-positive patients. Notably, two patients have shown long-term responses, remaining in the trial for over 104 weeks. A confirmed partial response in head and neck cancer supports progression in its trial phases. While NC318 is generally well-tolerated, the company will adjust its strategy for patient selection to improve outcomes.

NextCure, Inc. (Nasdaq: NXTC), a biopharmaceutical company focused on developing immunomedicines for cancer and immune-related diseases, will participate in a fireside chat at the Piper Sandler Virtual Healthcare Conference on December 1. The chat will feature a pre-recorded audio webcast accessible on their investors' section of the website, www.nextcure.com, and archived for 30 days. NextCure uses its proprietary FIND-IO™ platform to discover new treatments for patients unresponsive to existing therapies.

NextCure, Inc. (Nasdaq: NXTC) reported its third quarter 2020 financial results, highlighting ongoing clinical trials for NC318 and NC410. The company has $291.2 million in cash as of September 30, 2020, down from $334.6 million at the end of 2019, largely due to operational costs. R&D expenses increased to $12.7 million from $8.7 million year-over-year, while G&A expenses rose to $4.7 million from $2.6 million. Notably, there was no revenue this quarter, down from $1.6 million in Q3 2019, resulting in a net loss of $16.4 million, compared to $8.4 million last year.

NextCure, Inc. (Nasdaq: NXTC) appointed John G. Houston, Ph.D., to its board of directors on September 10, 2020. With over 30 years in the biotech sector, he currently serves as CEO of Arvinas, Inc. Dr. Houston's expertise in discovery biology and product development is expected to enhance NextCure's ongoing clinical trials for NC318 and NC410. Judith Li is stepping down from the board. The company focuses on developing first-in-class immunomedicines for cancer and immune-related diseases, utilizing its FIND-IO™ platform for novel treatment options.

NextCure, a clinical-stage biopharmaceutical company focused on immunomedicines for cancer and immune-related diseases, will present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 15 at 4:15 PM Eastern Time. The presentation will be accessible via a live audio webcast on NextCure's website, with a replay available for 30 days post-event. The company emphasizes its commitment to developing innovative therapies for patients unresponsive to existing treatments and relies on its FIND-IO platform for research and development.

NextCure, Inc. (NASDAQ: NXTC) reported its Q2 2020 financial results, revealing a net loss of $14.5 million compared to $8.2 million in Q2 2019. Cash reserves decreased to $309.3 million from $334.6 million in December 2019 due to operational costs. There was no revenue this quarter, a drop from $1.4 million last year. Despite setbacks in clinical trials for non-small cell lung and ovarian cancers, NextCure is encouraged by its ongoing trials for NC318 and has initiated the Phase 1 trial for NC410. Key milestones include patient enrollment in HNSCC and triple-negative breast cancer cohorts.

NextCure, a clinical-stage biopharmaceutical company focused on developing first-in-class immunomedicines for cancer and immune-related diseases, will present at the BTIG Virtual Biotechnology Conference on August 11 at 9:30 am ET. A live audio webcast will be accessible on NextCure's website, with a replay available two hours post-event and archived for 30 days. The company aims to address treatment gaps for patients unresponsive to current therapies through its proprietary FIND-IO™ platform.